IVIG Used as First-Line Monotherapy Attenuates Statin-Triggered Autoimmune Myopathy
Statin-triggered autoimmune myopathy can occur in rare instances where muscle-related symptoms fail to resolve following stoppage of the medication.
Short Course of IVIG May Slow Brain Atrophy and Conversion to Dementia in Persons with MCI Stage Alzheimer’s Disease
An exploratory controlled, randomized, double-blind study was conducted by investigators at the Sutter Neuroscience Institute in Sacramento to determine whether a single course of
intravenous immune globulin (IVIG) influences the rate of brain atrophy and cognitive function in mild cognitive impairment (MCI) due to Alzheimer’s disease (AD).
Immunodeficiency in Older Adults
Seven case studies unveil some of the immunodeficiencies affecting seniors.
Superbugs: Challenging Our Notions of Medical Supremacy
The growing number of strains of bacteria that are resistant to antibiotic treatment continues to plague patients and the healthcare community.
Future Biosimilars Pros and Cons
As biosimilars are introduced into the U.S. market, it remains to be seen whether FDA guidances will ensure their safety and efficacy.
Autoimmune Disease: A More Effective Treatment on the Horizon?
IVIG has enhanced and even saved the lives of many autoimmune disease patients. But, the cost of therapy, large dose size and limited raw materials are serious limitations to an otherwise efficacious, well-tolerated therapy.
Treating PANDAS
Current treatments for PANDAS have been shown to be relatively effective, but could surgical treatments such as tonsillectomy and adenoidectomy offer more effective results?
Precision Medicine: A Seismic Shift in Treatment Strategy
Still in its infancy, precision medicine holds out hope for moving directly from diagnosis to an effective tailor-fit treatment for each individual patient.
More Is Better: High-Dose Flu Vaccine Helps Protect Seniors
Influenza vaccination represents one of the most cost-effective treatment modalities available to the older adult population.
The Future Has Arrived: A Wave of New Products Is Redefining Hemophilia Care
New long-acting therapeutics are changing the way hemophilia is managed, creating more choice and better treatment compliance.
